THE Therapeutic Goods
Administration has approved
Actemra (tocilizumab) for the
treatment of systemic juvenile
idiopathic arthritis in patients two
years of age and older.
The approval for juvenile patients
follows the drug’s current availability
for adults with severe active
rheumatoid arthritis on the
Pharmaceutical Benefits Scheme.
Actemra works by blocking the
action of the body’s protein
messenger interleukin-6 which
contributes to chronic inflammation.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Nov 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Nov 11
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.